Skip to main content
INOVIQ LTD logo

INOVIQ LTD — Investor Relations & Filings

Ticker · IIQ ISIN · AU0000196149 ASX Professional, scientific and technical activities
Open in API
Filings indexed 858 across all filing types
Latest filing 2019-07-11 Capital/Financing Update
Country AU Australia
Listing ASX IIQ

About INOVIQ LTD

https://www.inoviq.com

INOVIQ LTD specializes in the development and commercialization of next-generation exosome and precision diagnostics. The company focuses on innovative solutions for the early detection and monitoring of cancer and other diseases. Its proprietary technology portfolio includes EXO-NET, a high-throughput exosome capture tool designed for research and clinical applications, and the SubB2M platform, which utilizes an engineered protein to detect the pan-cancer biomarker Neu5Gc. The company also provides the hTERT test for bladder cancer monitoring. These technologies facilitate non-invasive liquid biopsy tests aimed at improving patient outcomes through high sensitivity and specificity. The core business activities encompass the creation of diagnostic tools and research reagents for the global healthcare and life sciences sectors, emphasizing precision medicine and early intervention.

Recent filings

Filing Released Lang Actions
Appendix 3B and Cleansing Notice 708A 13 pages 436.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements related to these securities. It details the number and class of securities issued, terms of the securities, issue price, purpose of the issue, underwriting details, and compliance with ASX listing rules. The document includes detailed information about share issuance, entitlement offers, and placement capacity calculations under ASX rules. This type of document is not a financial report, earnings release, or management discussion but rather a formal announcement of a capital raising event and related securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication announcement but a substantive filing about capital changes.
2019-07-11 English
Completion of Capital Raising Package 2 pages 156.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement about the completion of a $7.5 million capital raising package by BARD1 Life Sciences Limited. It details the issuance of new shares, the amounts raised, and the strategic implications for the company. There are no financial statements or detailed financial performance data included. The content focuses on fundraising activities and capital structure changes. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is 4881 characters, which is sufficient for a detailed announcement but does not constitute a full financial report like an Annual or Interim Report.
2019-07-11 English
Closure of Entitlement Offer and Shortfall Notification 2 pages 98.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the closure of an entitlement offer and notification of a shortfall in subscription. It details the amount raised, underwriting agreements, and terms of the offer. There are no financial statements or detailed financial analysis present, only information about fundraising activities and share issuance. The document is not a full financial report, earnings release, or regulatory filing of financial results. It is clearly an update on capital raising activities, specifically an entitlement offer and related underwriting. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2019-07-09 English
Progress on Assay Development Program 2 pages 160.2KB
Capital/Financing Update Classification · 85% confidence The document is a company update on the progress of assay development for BARD1 autoantibody tests. It provides detailed information about the phases of development, technical milestones, and future plans related to the research and development of diagnostic tests. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content is focused on operational progress and product development rather than financial results or governance. It is not a report publication announcement since it contains substantive information rather than just announcing a report's availability. The document is best classified as a Capital/Financing Update (CAP) because it relates to development progress and potential commercialisation, which are typical of updates on company projects and capital deployment in R&D activities.
2019-06-30 English
Despatch of Offer Document 1 page 87.2KB
Capital/Financing Update Classification · 95% confidence The document is a short announcement regarding the despatch of an Offer Document and Entitlement and Acceptance Form related to a non-renounceable Entitlement Issue. It does not contain financial statements or detailed financial data, but rather informs shareholders about the sending of offer materials. The document length is only 1420 characters, indicating it is brief and primarily an announcement. This fits the category of Capital/Financing Update (CAP), as it relates to company fundraising activities and capital structure changes through an entitlement offer.
2019-06-25 English
Appendix 3Z - Montgomery 2 pages 181.3KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Z Final Director’s Interest Notice' and references ASX listing rule 3.19A.3 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including the number and class of shares held, and notes the date the director ceased to be a director. This is a report of personal share transactions or holdings by a company director. The document length is short and focused solely on director share interests, matching the definition of Director's Dealing filings.
2019-06-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.